IP Verse

Etherna Immunotherapies patent opposition analysis

CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Latest oppositions filed by Etherna Immunotherapies

Explore patent oppositions filed by Etherna Immunotherapies against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 14, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3853305
High-Purity Peg Lipids And Uses ThereofMODERNATXJun 27, 2025
EP3283059
Method For Producing Rna CompositionsCUREVACOct 3, 2024
EP3590949
Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses ThereofMODERNATXFeb 20, 2023
EP2791160
Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNA THERAPEUTICSDec 2, 2022
EP3682905
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMODERNATXAug 31, 2022
EP3173092
Rna Containing Composition For Treatment Of Tumor DiseasesCUREVACMar 26, 2020
EP3153179
Optimised Injection Formulation For MrnaCUREVACMar 18, 2020
EP3292873
Combination Of Vaccination And Inhibition Of The Pd-1 PathwayCUREVACFeb 3, 2020
EP2216028
Immunostimulation By Chemically Modified RnaCUREVACSep 6, 2018
EP2958588
Combination Of Vaccination And Inhibition Of The Pd-1 PathwayCUREVACMay 23, 2018

Top competitors of Etherna Immunotherapies

Top competitors of Etherna Immunotherapies based on patent oppositions.